Eli Lilly to Present Landmark monarchE Overall Survival Data for Verzenio in High-Risk Early Breast Cancer at 2025 ESMO Annual Meeting
Eli Lilly and Company announced that new data from its oncology portfolio and pipeline will be presented at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Meeting, scheduled for October 17-21 in Berlin, Germany. Presentations will include the primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer, as well as updated safety and efficacy results from investigational therapies targeting FRα positive ovarian cancer, KRAS G12C-mutant lung cancer, FGFR3-altered bladder cancer, and PIK3CA-mutant advanced breast cancer. Results from these studies will be presented at the ESMO meeting and have not yet been released.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE95319) on October 13, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。